Previous Close | 3.8100 |
Open | 3.8200 |
Bid | 3.9300 x 900 |
Ask | 4.0000 x 2900 |
Day's Range | 3.7250 - 3.8380 |
52 Week Range | 3.3000 - 7.0000 |
Volume | |
Avg. Volume | 993,610 |
Market Cap | 215.766M |
Beta (5Y Monthly) | 0.76 |
PE Ratio (TTM) | 93.75 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for VNDA
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.